Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia
Latest Information Update: 18 Mar 2024
At a glance
- Drugs Deferasirox (Primary) ; Deferiprone (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Acronyms START
- Sponsors ApoPharma; Chiesi
- 17 Jun 2022 Primary endpoint (The percentage of patients in each treatment group who still have a serum ferritin level 1000 micrograms per liter (g/L) at Month 12) has been met, as per results presented at the 27th Congress of the European Haematology Association.
- 17 Jun 2022 Results assessing ability of early-start DFP to shuttle iron to transferrin in infants and young children with transfusion-dependent beta thalassemia using transferrin-saturation (TSAT) measurements, presented at the 27th Congress of the European Haematology Association.
- 14 Dec 2021 Results assessing safety and efficacy of early-start deferiprone in infants and young children with beta-thalassemia, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.